Omitting Biopsy With Negative MRI Reduces Detection of Clinically Insignificant Prostate Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 27, 2024 -- Omitting biopsy in patients with negative magnetic resonance imaging (MRI) results is associated with a significantly reduced relative risk for detecting clinically insignificant prostate cancer, according to a study published in the Sept. 26 issue of the New England Journal of Medicine.
Jonas Hugosson, M.D., Ph.D., from Sahlgrenska Academy at the University of Gothenburg in Sweden, and colleagues invited men aged 50 to 60 years to undergo prostate-specific antigen (PSA) screening in a population-based trial that started in 2015. Men with a PSA of 3 ng/mL or higher underwent MRI of the prostate. Men were randomly assigned to the systematic biopsy group, in which they underwent systematic biopsy or targeted biopsy in the case of suspicious lesions on MRI, or to targeted biopsy only. Depending on the PSA level, men were invited for repeat screening two, four, or eight years later.
After a median follow-up of 3.9 years, the researchers found that prostate cancer was detected in 185 of the 6,575 men (2.8 percent) in the MRI-targeted biopsy group and in 298 of the 6,578 men (4.5 percent) in the systematic biopsy group. Detecting clinically insignificant cancer in the MRI-targeted biopsy group versus the systematic biopsy group had a relative risk of 0.43 (95 percent confidence interval, 0.32 to 0.57) and was lower at repeat rounds of screening (relative risk, 0.25 versus 0.49). For a diagnosis of clinically significant prostate cancer, the relative risk was 0.84 (95 percent confidence interval, 0.66 to 1.07).
"These results should encourage guideline committees to update recommendations around prostate cancer diagnosis and screening," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Racial Differences Seen in Prostate Cancer Care Quality
WEDNESDAY, July 30, 2025 -- Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared with White men, according to a...
Risk for Death From Prostate Cancer Low With Guideline Care for Nonmetastatic Disease
MONDAY, July 14, 2025 -- Men with nonmetastatic prostate cancer receiving guideline-concordant care have a much higher risk for death from causes other than prostate cancer...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.